PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.
| Author | |
|---|---|
| Abstract | :
Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and to establish factors predictive of this resistance. |
| Year of Publication | :
2017
|
| Journal | :
Oncotarget
|
| Volume | :
8
|
| Issue | :
69
|
| Number of Pages | :
113494-113501
|
| Date Published | :
2017
|
| DOI | :
10.18632/oncotarget.23054
|
| Short Title | :
Oncotarget
|
| Download citation |